Analysts Set Expectations for TSE:INO FY2027 Earnings

Inovalis Real Estate Investment Trust (TSE:INOFree Report) – Equities research analysts at Desjardins issued their FY2027 earnings per share estimates for shares of Inovalis Real Estate Investment Trust in a research report issued on Monday, November 17th. Desjardins analyst A. Leon anticipates that the company will post earnings per share of ($0.05) for the year.

Inovalis Real Estate Investment Trust Stock Performance

About Inovalis Real Estate Investment Trust

(Get Free Report)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Recommended Stories

Earnings History and Estimates for Inovalis Real Estate Investment Trust (TSE:INO)

Receive News & Ratings for Inovalis Real Estate Investment Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalis Real Estate Investment Trust and related companies with MarketBeat.com's FREE daily email newsletter.